Loading clinical trials...
Loading clinical trials...
A Phase 2, Single-Dose, Open-Label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies, in Patients Undergoing Routine Surgery
Conditions
Interventions
pegsitacianine
Tumor resection surgery
Locations
2
United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
April 13, 2022
Primary Completion Date
August 31, 2022
Completion Date
August 31, 2022
Last Updated
November 8, 2024
NCT05671510
NCT06498635
NCT03563976
NCT06257264
NCT03872661
NCT06646276
Lead Sponsor
OncoNano Medicine, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions